Where Will NuScale Power (SMR) Stock Be in 5 Years?

NuScale Power’s stock has fallen nearly 80% from its all-time high of $53.43 to about $12, reflecting delayed commercialization and weak near-term sentiment. Analysts still expect revenue to rise from $76 million in 2025 to $321 million by 2028, but the company remains deeply unprofitable and first meaningful reactor deployments are not expected until 2032-2034. Insider selling and Fluor’s full exit further signal limited near-term upside despite longer-term optionality.

Analysis

SMR is becoming a classic duration mismatch: the equity is still being priced off a multi-year commercialization story, while the business today is mostly a high-burn option on future licensing. That gap matters because every slip in first-unit timing compounds twice — it delays any credible recurring revenue and increases the probability that the company has to fund itself at less attractive terms before operating leverage ever arrives.

The more interesting second-order effect is on the ecosystem. FLR exiting is not just a sentiment signal; it reduces an implicit sponsor and execution buffer around the buildout narrative, which can make counterparties more conservative on project pacing, milestone gating, and prepayments. In a capital-intensive category, supplier and customer confidence can become self-reinforcing, so near-term weakness may be less about the reactors themselves and more about financing credibility.

Consensus seems to be anchoring on the long-run secular case for nuclear and AI power demand, but the market is underestimating how unforgiving the interim path is. SMR can still compound if it repeatedly de-risks deployment, yet the equity likely stays hostage to binary catalysts over the next 12-24 months: further schedule slippage, NRC/process surprises, or evidence that TVA/RoPower milestones are slipping would likely compress the multiple faster than revenue can grow. The upside is real, but it is being financed by patience, and patience is the scarce input here.

For FLR, this is marginally negative to the extent it signals lower strategic optionality around SMR-adjacent engineering revenue, but the more important read-through is that the market may be overvaluing early-stage nuclear exposure versus execution certainty elsewhere in infrastructure. If nuclear buildout in the U.S. is real, the better risk-adjusted winners may be the contractors, component suppliers, and grid infrastructure names that monetize project activity before first electrons are ever generated.

Key Decisions for Investors

• Avoid outright long SMR here; if initiating exposure, prefer a small starter long only on a confirmed milestone close (formal financing, EPC award, or schedule de-risking) rather than on narrative alone. Time horizon: 6-18 months. Risk/reward: asymmetric only if execution accelerates; otherwise downside remains high as duration gets repriced.
• Pair trade: long FLR vs short SMR for 3-9 months if you want nuclear exposure with lower binary risk. FLR monetizes infrastructure spend immediately, while SMR remains dependent on future delivery; the spread should favor the cash-generating contractor if project enthusiasm persists but timelines keep slipping.
• Buy SMR puts or put spreads into any strength over the next 1-3 months ahead of the next catalyst window. This is a good expression of 'good story, bad timing' and limits upside risk if sentiment turns on another delay.
• Favor a basket of nuclear-adjacent infrastructure beneficiaries over pure-play reactor developers: utilities, EPCs, and grid equipment names that can capture early-stage spending. Time horizon: 12-24 months. Risk/reward: better cash conversion and lower execution beta than SMR.
• If holding SMR, use a hard risk stop tied to milestone failure rather than price alone; a missed deployment date or financing setback is likely to trigger a much larger multiple reset than the stock currently discounts.